Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

PHASE3CompletedINTERVENTIONAL

Enrollment

613

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

February 28, 2007

Conditions

Mixed DyslipidemiaCoronary Heart DiseaseDyslipidemia

Interventions

DRUG

ABT-335

135 mg, daily, 12 weeks

DRUG

Atorvastatin

Daily, 12 weeks, see Arm Description for dosage information

DRUG

Placebo

daily, 12 weeks, see Arm Description for placebo information

Trial Locations (1)

Global Medical Information, North Chicago